Business Wire

CO-OPTIV-SECURITY

3.6.2019 20:07:03 CEST | Business Wire | Press release

Share
Optiv Security Doubles Down On Client Success with New Services Approach, Business and Engagement Model; Further Advances Ability to Help Global Clients Optimize, Integrate and Operationalize Cybersecurity

While industries are being completely reinvented at an ever-accelerating pace, the overall approach to cybersecurity has not similarly evolved to address the new security challenges presented by rapid digital transformation. Talent shortages, expanding attack surfaces, and constant breaches are all symptoms of an unnecessarily complex and inefficiently constructed cybersecurity world. Optiv Security , a global cybersecurity integrator delivering end-to-end cybersecurity solutions, today announced it has implemented a new cybersecurity services approach, business and engagement model that transforms the way cybersecurity is consumed and applied. Optiv’s innovative approach is specifically designed to deliver to organizations integrated cybersecurity solutions that address the speed of business change, by providing new consumption and outcome-based consulting services and cybersecurity solutions that ultimately achieve higher performance and reduced overall operational costs.

Specifically, the company is launching the following to more tightly align its breadth of capabilities and client-centric approach, to bring to market more focused global cybersecurity solutions that encompass people, process and technology.

  • Newly launched Global Services and Operations Organization – Optiv has redesigned its services approach centered on client-focused outcomes and is delivering global capabilities to assist clients along their cybersecurity journeys. The company’s breadth of services addresses the full lifecycle of client security needs – with newly launched business lines for Advisory, Integration & Innovation, and CyberOperations - providing global clients with the required focus and scale to execute on full end-to-end cyber risk, cyber digital and cybersecurity projects and programs.
  • Cyber-as-a-Service (CaaS TM ) Platform – designed to ensure organizations benefit from fully-integrated solutions that scale on-demand with business needs and automatically adapt to shifting business requirements. This approach enables Optiv to deliver complex and integrated solutions with an innovative integrated technology stack focused on client outcomes. Optiv’s new CaaSTM offerings can be consumed alone, or combined with Optiv’s advisory, integration or managed services to harden security fundamentals across four critical areas of modern business risk:
    • Risk management and compliance, including resilience and assurance;
    • Cyber digital transformation, including cloud, orchestration, automation and big data;
    • Threat management, including protection, detection and response; and
    • Identity and data management.
  • Global Services Demand (GSD) Organization – Coordinating Partner and Teaming Delivery Model – Optiv created GSD to provide clients with the optimal mix of centralized oversight and buying power, and localized technical resources and expertise. This new engagement model also brings together a seasoned team of regionally-focused senior technical services executives to give clients an important engagement layer atop Optiv’s more than 1,300 deeply skilled and specialized cybersecurity delivery practitioners. These executives serve as global coordinating partners for our clients, acting as a single point of accountability to drive excellence for complex end-to-end cybersecurity services and solutions.

“After more than 40 years since the first virus was launched, the approach to addressing cybersecurity issues has followed the same action and response formula. The challenge is that the world has changed, while the approach to cybersecurity has not kept pace,” said Chad Holmes, chief services and operations officer. “Industries are being completely reinvented – through digital transformation, cloud and data models, Artificial Intelligence (AI), globalization and much more – while cybersecurity gaps expand as symptoms of a historical approach to a new and different business model.”

Holmes continued, “Our new Cyber-as-a-Service consumption model, which we are launching based on client feedback and to meet growing market demand, strongly complements our traditional services model. It enables clients to have a choice in their cybersecurity consumption model, and thereby transform their organizational cybersecurity approach, while benefiting from the same cloud economics that have been used to transform entire industries. This custom developed, innovative and integrated approach provides organizations with increased flexibility and choice in how they procure cybersecurity – from standalone tools to integrated solutions – addressing complex security problems and delivering better alignment to unique business requirements. Optiv is extremely excited to bring to market our new Cyber-as-a-Service, integrated business services and client engagement models, that will increase our ability to provide clients with the right global resources at the right time so that we can truly serve their best interests.”

Please visit our website for more information about our cybersecurity solutions and capabilities.

Follow Optiv
Twitter: www.twitter.com/optiv
LinkedIn: www.linkedin.com/company/optiv-inc
Facebook: www.facebook.com/optivinc
YouTube: https://www.youtube.com/c/OptivInc
Blog: www.optiv.com/resources/blog

About Optiv Security

Optiv is a global cybersecurity solutions integrator – a “one-stop” trusted partner with a singular focus on cybersecurity. Our end-to-end cybersecurity capabilities span risk management and transformation, cyber digital transformation, threat management, cyber operations, identity and data management, and integration and innovation, helping organizations realize stronger, simpler and more cost-efficient cybersecurity programs that support business requirements and outcomes. At Optiv, we are modernizing cybersecurity to enable clients to innovate their consumption models, integrate infrastructure and technology to maximize value, achieve measurable outcomes, and realize complete solutions and business alignment. For more information about Optiv, please visit us at www.optiv.com .

Contact:

Jason Cook (816) 701-3374 Jason.cook@optiv.com or Brett Ater (913) 304-7683 Brett.ater@optiv.com

Link:

ClickThru

Social Media:

https://www.facebook.com/OptivInc

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye